Christine Yanicek | Jun 29, 2003 | 3 min read
Courtesy of Bruker Daltonics Bruker Daltonics of Billerica, Mass., has developed a new mass spectrometry system that the company describes as a "holistic solution" for clinical proteomics and biomarker discovery. The ClinProt™ system, encompassing automated sample preparation, high-performance matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) analysis, and back-end bioinformatics, is the brainchild of Bruker CEO Frank Laukien, who wanted to target the biomarker disc